GTT Communications
NYSE:GTTGTT Communications, Inc. provides cloud networking services to multinational enterprises, carriers, and government customers in the United States, Europe, and internationally. The company offers wide area networking, such as software-defined wide area networking, multiprotocol label switching, and virtual private LAN service; high bandwidth-Internet connectivity and IP transit, as well as broadband and wireless Internet access services; managed equipment and security services; and unified communication services consisting of session initiation protocol trunking, cloud unified communication service, and traditional analog voice. It also provides transport services, such as Ethernet services that enable to design network equipment; and video transport services to support broadcast quality transmission of live events, sports entertainment, and news to media and entertainment industry. In addition, the company offers infrastructure services enabling transport of high volume data between data centers, enterprise office locations, and media hubs; wavelength services to deliver scalable high-performance optical connectivity; colocation, turnkey, duct, and dark fiber services; advanced solutions, including security, hybrid cloud, database, and application management Its IP network consists of approximately 600 points of presence. GTT Communications, Inc. markets its products and services through a network of direct sales force and indirect sales channels. The company was formerly known as Global Telecom & Technology, Inc. and changed its name to GTT Communications, Inc. in January 2014. GTT Communications, Inc. was founded in 2005 and is headquartered in McLean, Virginia.
Novo Nordisk A/S
NYSE:NVONovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
